Xilio Therapeutics to Present at Cowen 6th Annual ‘IO Next’ Summit
November 04 2022 - 7:30AM
Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company
developing tumor-activated immuno-oncology therapies for people
living with cancer, today announced that the company will
participate in a virtual fireside chat at the Cowen 6th Annual IO
Next Summit on Friday, November 11, 2022, at 1:40 p.m. ET.
A live webcast of the presentation can be accessed under “Events
& Presentations” in the Investors & Media section of the
Xilio Therapeutics website at https://ir.xiliotx.com/. A
replay of the webcast will be archived on the website for 30 days
following the presentation.
About Xilio Therapeutics
Xilio Therapeutics is a clinical-stage biotechnology company
focused on harnessing the immune system to achieve deep and durable
clinical responses to improve the lives of patients with cancer.
The company is using its proprietary geographically precise
solutions (GPS) platform to rapidly engineer novel molecules,
including cytokines and other biologics, that are designed to
optimize their therapeutic index. These molecules are designed to
localize activity within the tumor microenvironment without
systemic effects, resulting in the potential to achieve enhanced
anti-tumor activity. Xilio is building a pipeline of wholly owned,
tumor-activated product candidates, including its clinical-stage
programs, XTX101, a tumor-activated anti-CTLA-4 monoclonal
antibody, and XTX202, a tumor-activated IL-2, as well as its
earlier pipeline, including XTX301, a tumor-activated IL-12. For
more information, please visit https://xiliotx.com and follow
us on Twitter (@xiliotx) and LinkedIn (Xilio Therapeutics,
Inc.).
For Investor Inquiries:Myles CloustonVice
President, Investor Relationsinvestors@xiliotx.com
For Media Inquiries: Julissa VianaVice
President, Corporate Communicationsmedia@xiliotx.com
Xilio Therapeutics (NASDAQ:XLO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Xilio Therapeutics (NASDAQ:XLO)
Historical Stock Chart
From Apr 2023 to Apr 2024